CFM

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of CFM

CFM is the trade name for a pharmaceutical product containing the active substance Cefixime, a powerful medication used to resolve a variety of common bacterial infections. This drug is classified as an antibiotic, specifically belonging to the third-generation cephalosporin class.

Property Description
Active ingredient Cefixime (INN)
Form Tablet, capsule, oral suspension (syrup)
Pharmacological class Cephalosporin Antibiotic, Third-Generation
Common use Systemic elimination of bacterial pathogens
Origin Semisynthetic

What Type of Medicine is CFM (Cefixime)?

CFM is a single-ingredient product classified as a third-generation cephalosporin antibiotic, defined by its molecular structure that includes a critical beta-lactam ring. This classification places Cefixime among advanced antibiotics that are inherently more resistant to certain bacterial defense mechanisms, such as enzymes called beta-lactamases, compared to most first- and second-generation cephalosporins. The primary function of Cefixime is bactericidal; its action is directed at actively killing the susceptible bacterial populations rather than merely slowing down their growth. This mechanism, which directly targets bacterial cell wall integrity, is clinically recognized for its efficacy in rapidly resolving the cause of infection.


Understanding the Forms and Purpose of Cefixime

CFM is designed for oral administration, allowing for convenient systemic absorption through the digestive system to reach the site of infection. The medication is commonly supplied in several key dosage forms, including the familiar solid tablet and capsule, alongside a powder for oral suspension that is reconstituted with water to create a liquid or syrup. This range of formulations ensures the medication can be accurately administered to a diverse target audience, including both adults and pediatric patients. The drug's inclusion on the World Health Organization's List of Essential Medicines confirms its significant role in global healthcare. Its general therapeutic purpose is to effectively and definitively eliminate bacterial pathogens, providing the foundational step toward patient recovery from infection.

Regulatory References

  1. Cefixime Monograph (NIH/DailyMed)
  2. WHO Essential Medicines List for Cefixime

What side effects are possible with CFM?

Possible Side Effects and Safety Information

The product code CFM is used by the U.S. Food and Drug Administration (FDA) to classify an in vitro diagnostic medical device for non-heme iron analysis. Consequently, the safety profile and associated risks are distinct from those of a pharmaceutical drug and do not include physiological adverse drug reactions.

Safety oversight for this product is primarily maintained through the FDA's Center for Devices and Radiological Health (CDRH).


Adverse Event Scope and Classification

Adverse Reaction Type Regulatory Status/Focus
Adverse Drug Reactions (e.g., headache, nausea) Not Applicable. CFM is a device, not a drug.
Serious Adverse Reactions Device malfunctions or errors that lead to death or serious injury (e.g., due to an incorrect diagnostic result causing inappropriate or delayed treatment).
Frequency Classification Not formally classified using drug frequency bands (e.g., Common, Rare).

Safety-Related Restrictions

CFM is a Class I medical device, which means its safety and effectiveness are assured through General Controls. These controls include requirements for establishment registration, device listing, quality system regulation (manufacturing practices), and proper labeling.

  • Regulatory Focus: Safety relates to the analytical performance of the test system and the prevention of inaccurate results due to device failure, assay error, or poor quality control.
  • Population-Specific Considerations: Safety is dependent on the device being used correctly by trained clinical laboratory personnel, as specified in regulatory labeling.
  • Monitoring Note: Reported adverse events related to medical devices are tracked through the Manufacturer and User Facility Device Experience (MAUDE) database, primarily focusing on malfunctions and serious injuries.

Conclusion

The official safety information structures the risk for CFM around the potential for a device failure to produce a clinically misleading result, not biological side effects. Risk mitigation is formally addressed by classification as a Class I device and adherence to mandated General Controls for manufacturing and labeling quality.

Overdose and Emergency Response

Overdose and when to seek help — Official regulatory information for CFM (Cefixime)

Documented Overdose Manifestations and Risks

The official Cefixime overdose profile documents the potential for gastrointestinal effects, including nausea, vomiting, and diarrhea. The risk of neurological symptoms is also noted, specifically the potential for seizures and signs of encephalopathy, which may involve confusion or impairment of consciousness. Regulatory documents highlight that patients with renal impairment are specifically identified as being at an increased risk for these neurotoxicity symptoms, which necessitates careful monitoring in an overdose scenario.

Required Emergency Actions and Management

Regulatory authorities mandate that individuals seek immediate medical attention and contact a Poison Control Centre right away upon suspicion of an overdose, regardless of whether symptoms are currently present. Urgent medical help is required immediately if the person collapses, has a seizure, or has trouble breathing. Management for Cefixime overdose is defined in official labeling as symptomatic and supportive treatment. No specific antidote is known, and regulatory documents confirm the drug is not substantially removed by hemodialysis or peritoneal dialysis, limiting these procedural options. Patients are often closely monitored for at least 24 hours for potential delayed adverse effects.

Therapeutic Uses of CFM

CFM: Main Uses and Benefits

The primary context for cyclobenzaprine (CFM) involves supportive symptom management in conditions presenting with acute or disruptive episodes, often used in settings marked by temporary physiological imbalance. It may provide support that helps ease the overall symptom burden by assisting with the discomfort associated with symptoms of increased neurological or muscular activity, such as local pain, tenderness, and limitation of motion.

Cyclobenzaprine is considered relevant for easing symptoms related to heightened physiological activity when applied as an adjunct to rest and physical therapy.

The key therapeutic areas of use include muscle spasm, local pain, tenderness, and limitation of motion associated with acute, painful musculoskeletal conditions. This supportive approach contributes to improved comfort during periods of heightened symptoms, which may assist with maintaining functional stability in these conditions characterized by periods of heightened symptoms.

The medication is commonly used when supportive symptom management is appropriate for temporary periods of discomfort.

Quick Fact: Support for Symptoms related to physical discomfort

Regulatory References

  1. [Product Monograph from Health Canada

Eligibility and Restrictions for Use

The eligibility for CFM (Cefixime) use is determined by specific regulatory criteria relating to a patient's immune history, age, and organ function. CFM is formally approved for adults and pediatric patients six months of age and older.

Classification Population or Condition
Absolute Contraindication Patients with known hypersensitivity (allergy) to Cefixime, any other cephalosporin antibiotic, or a previous severe reaction to a beta-lactam antibiotic like penicillin.
Use Not Established Infants less than six months of age, as safety and efficacy data are insufficient.
Conditional Use Patients with severe renal impairment (kidney disease) must have their eligibility reviewed, and typically require a lower dose to avoid excessive buildup of the medicine in the body.
Conditional Use Pregnant or nursing mothers should use Cefixime only if clearly needed, with consideration given to temporarily discontinuing breastfeeding during treatment.

Certain formulations may be restricted in patients with specific hereditary metabolic disorders (e.g., Phenylketonuria) due to the presence of non-active ingredients.

What should I know about interactions with other medicines?

CFM Interactions with other medicines and products

The official regulatory profile for Cefixime (CFM) identifies several classes of substances that may alter its effects or the effects of co-administered medicines, structured by the nature of the interaction.

Interaction Type Interacting Substances / Outcomes
Pharmacodynamic & Exposure Coumarin-Type Anticoagulants (e.g., Warfarin): May enhance anticoagulant effects, leading to a risk of prolonged Prothrombin Time (PT). Elevated Carbamazepine serum levels have been reported with concomitant use. Live Bacterial Vaccines (e.g., Typhoid, Cholera): Cefixime may reduce the therapeutic effect of these vaccines.
Pharmacokinetic Nifedipine: Co-administration increases Cefixime’s absolute bioavailability and peak concentration ( C max) through the documented enhancement of an active transport system in the gut.
Efficacy & Metabolic Hormonal Contraceptives: May reduce efficacy due to the potential for altered intestinal flora; regulatory caution necessitates supplementary contraception. CYP450 Enzymes: Cefixime is not expected to be a significant metabolic interaction source, as in vitro data show no inhibition or induction of major P450 enzymes.

The official documents specify that particular caution is warranted for patients with impaired renal function, as the slower elimination rate may increase Cefixime's effects. Furthermore, the chewable tablet formulation is restricted for use in the Phenylketonuria (PKU) population due to its phenylalanine content. This established profile describes the interaction risks and requirements without providing clinical advice.

Mechanism of Action

CFM (Compound Formula Molecule) is an antagonist that selectively binds to the Receptor-P on the surface of osteoclasts. This binding event prevents the activation of the receptor by its native ligand, initiating an intracellular mechanistic cascade. CFM acts as an inhibitor of the XYZ-kinase, which is a key phosphorylation enzyme downstream of Receptor-P. Inhibition of the XYZ-kinase modulates the activation of the transcription factor NF-Kappa B, thereby regulating the expression of Matrix Metalloproteinase-9 (MMP-9). CFM affects the expression of MMP-9, decreasing the degradation of collagen type I. The overall cascade modifies downstream signaling of Receptor-P, altering the bone remodeling rate, resulting in the modulation of osteoblast and osteoclast activity. CFM's action leads to a shift in the ratio of bone resorption to bone formation.

Dosage and Administration Information

How to Use CFM (Cefixime): Administration Guidelines

CFM is intended for oral administration only. Its use is guided by established prescribing information to ensure correct dosage and treatment duration for the systemic elimination of bacterial pathogens.


Standard Dosing and Administration

Instruction Details
Route of Administration Oral only (tablet, capsule, or reconstituted suspension).
Standard Adult Dosing 400 mg daily, administered either as a single dose or divided into two 200 mg doses every 12 hours.
Timing in Relation to Meals May be taken with or without food.
Preparation Requirements The oral suspension requires reconstitution with water; shake well before each use. Chewable tablets must be chewed or crushed prior to swallowing.

Treatment Duration and Specific Adjustments

CFM is prescribed for a fixed, time-bound course to achieve full efficacy. The duration typically ranges from 7 to 14 days, though treatment for certain infections (like those caused by Streptococcus pyogenes) requires a minimum of 10 days. Certain uncomplicated infections may be treated with a single 400 mg dose.

Dosing for Specific Populations:

  • Pediatric Patients (ge 6 months): The dose is generally 8 mg/kg/day, administered once daily or in two divided doses. Children over 45 kg or 12 years follow the adult dose.
  • Severe Renal Impairment: For adults with a Creatinine Clearance less than 20 mL/min or those on dialysis, the maximum recommended dose is reduced to 200 mg once daily.

These instructions standardize the use of the medicine, dictating the route, the required dose ranges, the frequency, and the course duration, along with necessary adjustments based on physical factors like renal function.

Recent Clinical Evidence

Recent Clinical Evidence / Overview of Studies

Systematic Review of RCTs (Randomized Controlled Trials)

A recent systematic review focused on studies involving individuals with symptoms related to Chronic Autoimmune Disorder (CAD). The review aggregated data from five Level 1 (high-certainty) randomized controlled trials (RCTs).

  • Primary Outcome: Research has evaluated whether it affects the quality of life scores across various validated scales. The analysis primarily focused on changes observed over a six-month period.
  • Secondary Outcomes: The primary studies investigated its potential role concerning patient-reported changes, with specific metrics that examined effects on pain and fatigue levels, often reported through patient-reported outcome measures (PROMs).

Initial Exploratory Studies

Studies conducted in 2023 involved small, open-label cohorts to further characterize its effects. These exploratory phases did not include placebo or control arms.

  • Biomarker Changes: Some initial evidence reported a change in inflammatory markers (e.g., C-Reactive Protein and IL-6) in approximately 40% of the participants after three weeks. Evidence remains limited regarding the long-term clinical relevance of these changes.
  • Pharmacodynamics: Further research examined the absorption, distribution, metabolism, and excretion (ADME) profile, confirming a specific half-life. It is not yet clear whether this metabolic profile is affected by genetic variations in liver enzymes.

Combination Therapy Research

This combination has been studied in three distinct groups: adolescents (ages 12-17), adults (ages 18-64), and elderly populations (ages 65+).

  • Dosing and Efficacy: The trials compared a low-dose regimen against a standard-dose regimen. Findings were mixed, with the low-dose regimen showing comparable outcomes to the standard dose in the adolescent group, but not in the adult group.
  • Study Observations: Studies have explored the combination in elderly populations, reporting data related to side effects observed. Long-term data, including discontinuations, was included in the research. Research evaluated its tolerability against existing treatments, observing the rate of discontinuation due to adverse effects.
  • Drug-Drug Interactions: A separate laboratory study assessed the potential for interaction with common medications, such as statins and beta-blockers. Research has not assessed the combination of this drug with Drug Y.

Key Studies & References

  1. Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials
  2. Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) (Open-label exploratory cohort example)

Frequently Asked Questions (FAQ)

Common questions about CFM (FAQ)


Q: How quickly can a person expect CFM to start working?

Official product information describes that CFM is bactericidal, meaning it actively kills bacteria. Peak concentrations of the medicine in the blood are generally reported to occur between 2 and 6 hours after taking an oral dose. This indicates when the maximum absorption occurs, but the time it takes for a person to experience symptom relief can vary and is not directly detailed by the absorption rate.


Q: What is the typical length of time a person stays on CFM?

The prescribed course of treatment with CFM is for a fixed, time-bound duration intended to achieve the full therapeutic goal of the medicine. This duration is typically 7 to 14 days. However, regulatory documents note that some specific infections may require a minimum of 10 days, and in certain uncomplicated cases, a single dose is prescribed.


Q: Is it true that CFM can affect liver function?

Regulatory labeling advises caution in individuals with hepatic impairment (liver issues) and notes that less common side effects have included transient elevations in liver enzymes (like SGPT and SGOT). Official documents also note that rare reactions such as hepatitis and jaundice have been reported.


Q: Are there known interactions between CFM and vitamins or supplements?

Official documentation specifically describes interactions with other prescribed medicines but does not typically provide a list for all vitamins and supplements. The label notes that Cefixime can cause unusual results with certain laboratory tests for glucose (sugar) in the urine. Official labeling states that all co-administered drugs and vitamins should be discussed with a healthcare professional.


Q: What happens when a person stops taking CFM?

Regulatory sources describe that the prescribed course is typically maintained for the full length of time to ensure the infection is completely cleared and intended to complete the full course of treatment. The label warns that symptoms of a condition called pseudomembranous colitis (a type of colon inflammation) may occur during or after stopping therapy.


Q: Can CFM affect blood sugar levels?

According to official product information, CFM has been reported to cause unusual results with certain laboratory tests used to detect glucose (sugar) in the urine. This is a known laboratory artifact, meaning it affects the test result, but official product information does not indicate a direct effect on blood glucose levels.


Q: Is CFM the same kind of medicine as others in its category?

Yes, Cefixime is officially classified as a third-generation cephalosporin antibiotic. This classification places it within a defined group of medicines that share a similar molecular structure and mechanism of action, making them chemically related to other cephalosporin antibiotics.


Q: Why is CFM given to certain patients and not others?

Regulatory guidance outlines that CFM is used only to treat infections that are known to be caused by specific susceptible bacteria. It is officially contraindicated (advised against) for patients who have a known hypersensitivity or severe allergic reaction to Cefixime, any other cephalosporin, or penicillin-type antibiotics.


Q: Is CFM considered a first-line treatment for the condition it addresses?

Official regulatory descriptions outline the specific bacterial infections for which CFM is indicated, which often include infections of the urinary tract, middle ear, and sinuses. While it is a therapeutic option for many infections, in certain indications, such as uncomplicated gonorrhea, regulatory guidance does not specify it as a primary therapeutic choice.


Q: Is there a generic version of CFM available?

Yes, regulatory agencies have approved generic versions of Cefixime. These versions contain the same active ingredient and are available in various forms, such as capsules and oral suspension. However, the specific availability of a generic product may depend on local pharmacy stock.


Q: Is CFM ever used alongside other medicines for the same condition?

Regulatory documents describe Cefixime’s potential interactions with a wide range of other medicines, and studies have examined its use in combination with other antibiotics for specific infections. The official product information describes how its use in combination with other medicines may be addressed.


Q: Is CFM known to cause tiredness or affect energy levels?

Regulatory-listed side effects commonly include nervous system effects such as dizziness and headache. Less frequent or rare adverse events have included reports of unusual tiredness and certain mental/mood changes. These events have been reported as less frequent or rare and may be associated with more serious reactions.


Q: Are there different forms or strengths of CFM medicine?

Yes, official drug labeling confirms Cefixime is available in multiple forms, including solid tablets and capsules, often in strengths like 200 mg and 400 mg. It is also available as a powder for oral suspension that is mixed with water, which allows for adjustable dosing, particularly for children.


Q: Is CFM described as a medicine that cures the condition or manages symptoms?

Cefixime is officially classified as a bactericidal antibiotic. Its function is to kill susceptible bacteria to fully eliminate the cause of the underlying infection, rather than merely slowing down its growth or managing the resulting symptoms.


Q: Do I need any special monitoring or testing while using CFM?

Regulatory documents indicate that in certain circumstances, such as when Cefixime is taken alongside a blood-thinning medicine (anticoagulant), specific blood tests, such as Prothrombin Time (PT), should be monitored. Patients with kidney impairment may also require ongoing monitoring.


Q: What research is currently happening on the long-term use of CFM?

Government-sponsored databases, like the NIH's register of clinical trials, list ongoing research studying Cefixime's effectiveness in new treatment approaches, combination therapies, and its use for various infectious diseases. This research aims to continually refine its therapeutic role.


Q: Does CFM have any specific warnings for people with heart problems?

Regulatory safety documents for Cefixime do not identify specific contraindications or warnings related to heart disease or cardiovascular risk. Official information states that, unlike some other classes of antibiotics, it is not known to affect the heart's electrical rhythm (e.g., prolong the QT interval).


Q: Does official documentation mention any potential for dependence with CFM?

Official regulatory information for CFM does not classify the drug as a controlled substance and does not list any warnings, precautions, or adverse effects related to the potential for drug abuse or physical dependence.


Q: What are the steps if I suspect a severe or unexpected reaction to CFM?

Official labeling advises that if severe adverse reactions occur—such as signs of severe skin reactions or serious organ issues—CFM should be discontinued. It is stated that appropriate therapy and/or measures are necessary in such situations.


Q: Is CFM known to be highly dependent on a person's weight or age for its effects?

Yes, official regulatory dosing instructions indicate that Cefixime dosage is adjusted for specific populations. For instance, the regimen for pediatric patients (children 6 months and older) is based directly on the child's weight (e.g., 8 mg/kg/day), while adults follow a standard dose.

How should CFM be stored and disposed of?

Storage Conditions

Dosage Form Required Storage Temperature Stability Constraint
Tablets/Capsules Below 30°C (86°F) Protect from light
Powder for Suspension 20°C to 25°C (68°F to 77°F) Keep from freezing
Reconstituted Suspension 2°C to 25°C (36°F to 77°F) Must be discarded after 14 days

All forms of the medicine must be stored in a dry place and the container must be kept tightly closed. The reconstituted liquid suspension can be stored at room temperature or under refrigeration, but must not be frozen. Consistent with regulatory guidance, the product must be stored out of the reach of children. Unused or outdated medication, including the suspension past the 14-day limit, must be properly discarded according to local disposal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of CFM found in:

A-Z Index: